PROGNOSTIC IMPACT OF NPM1 AND FLT3 MUTATIONS IN PATIENTS WITH LMA IN FIRST REMISSION RECEIVING ORAL AZACITIDINE MAINTENANCE.
The trial conducted by Hartmut Döhner and his research group has shown that, compared to placebo, oral azacitidine improved overall survival in patients with acute myeloid leukemia (AML) in first remission after chemotherapy who were not candidates for stem cell transplantation. This analysis found that the azacitidine-associated survival improvement was independent of NPM1 and FLT3 […]
